The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
The effects of fibrates on lipoprotein profiles and lipoprotein physiology, as well as on selected coagulation and fibrinolytic factors are reviewed. It is concluded that the action of fibrates on these systems is such as to render the fibrates beneficial in atherosclerosis prevention.
Schonfeld
G
G
Div. Atherosclerosis, Nutrition and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110.
D001161:Arteriosclerosis / Q000188:drug therapy / Q000517:prevention & control; D001629:Bezafibrate / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy / Q000517:prevention & control; D011345:Fenofibrate / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D058607:Fibric Acids; D015248:Gemfibrozil / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D000960:Hypolipidemic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D008074:Lipoproteins / Q000187:drug effects* / Q000378:metabolism; D012307:Risk Factors
D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D002995:Clofibric Acid; C019304:ciprofibrate; D015248:Gemfibrozil; D011345:Fenofibrate; D001629:Bezafibrate